


Meeting report of the **WHO** expert consultation on drug-resistant tuberculosis treatment outcome definitions


17-19 November 2020



World Health
Organization

Meeting report of the **WHO** expert consultation on drug-resistant tuberculosis treatment outcome definitions

17-19 November 2020



Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17-19 November 2020

ISBN 978-92-4-002219-5 (electronic version)

ISBN 978-92-4-002220-1 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17–19 November 2020. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents	
Abbreviations.....	iv
Executive summary	v
1. Background	1
1.1. Introduction and history	1
1.2. Pre-2021 treatment outcome definitions for DR-TB and DS-TB.....	2
1.3. Advances in treatment of TB and diagnostics for treatment monitoring...	4
1.4. Rationale for the change.....	5
1.5. Consultation objectives	6
2. Summary of the consultation	8
2.1. Setting the scene for the consultation.....	8
2.2. Proposed options for new definitions of TB treatment outcomes	10
2.3. Principles and strategic issues to guide the development of new definitions of treatment outcomes.....	10
2.4. Operational issues in relation to revision of the specific treatment outcome definitions	11
3. Consultation outcomes: the new definitions of TB treatment outcomes.....	16
4. Next steps	17
Annex 1: Historical and current definitions of treatment outcomes for patients with drug-susceptible or drug-resistant tuberculosis	18
Annex 2: Proposed revisions to treatment outcome definitions from the scientific literature.....	21
Annex 3: Treatment outcome definitions for patients with rifampicin resistant, multidrug-resistant and extensively drug-resistant tuberculosis treated using novel second-line treatment regimens as part of clinical trials	23
Annex 4: Agenda for the consultation meeting on the drug-resistant tuberculosis treatment outcome definitions	25
Annex 5: List of participants for the consultation meeting on the drug-resistant tuberculosis treatment outcome definitions	26
Annex 6: Options proposed for discussion at the consultation meeting on the update of treatment outcome definitions for patients treated for drug resistant and drug susceptible tuberculosis	29
References	32

Abbreviations

ADR	adverse drug reaction
AIDS	acquired immunodeficiency syndrome
BPaL	bedaquiline, pretomanid and linezolid
DNA	deoxyribonucleic acid
DR-TB	drug-resistant tuberculosis
DST	drug-susceptibility testing
DS-TB	drug-susceptible tuberculosis
HIV	human immunodeficiency virus
MDR/RR-TB	multidrug-resistant or rifampicin-resistant tuberculosis
MDR-TB	multidrug-resistant tuberculosis
NTP	national tuberculosis programme
RNA	ribonucleic acid
RR-TB	rifampicin-resistant tuberculosis
TB	tuberculosis
WHO	World Health Organization
XDR-TB	extensively drug-resistant tuberculosis

Executive summary

The World Health Organization (WHO) held an online consultation on the definitions of drug-resistant tuberculosis (DR-TB) treatment outcomes, on 17–19 November 2020. Organized by the WHO Global TB Programme, Geneva, Switzerland, the consultation was attended by 66 participants, representing countries, bilateral and multilateral agencies, international organizations, nongovernmental organizations, civil society and academia.

The consultation discussed recent and potential future developments in treatment regimens for both DR-TB and drug-susceptible TB (DS-TB) and considered possible changes to the treatment outcome definitions needed for programmatic monitoring. The specific objectives of the consultation were to discuss:

- recent developments in treatment regimens and in diagnostics for monitoring treatment of DR-TB, and to determine how these developments affect the current definitions of treatment outcomes; and
- options for changing the treatment outcome definitions, including the pros and cons of these options from various perspectives (e.g. clinical, programmatic and surveillance).

The online consultation ran for a total of 9 hours, with a 3-hour session on 3 consecutive days. Most of the time was devoted to discussion of four topics:

- recent developments in tuberculosis (TB) treatment and diagnostics for treatment monitoring;
- principles and strategic issues that will underlie the new definitions of treatment outcomes;
- operational issues related to the definitions of treatment outcomes; and
- an outline of the new definitions of treatment outcomes, including next steps.

Before the meeting, the WHO Global TB Programme shared a concept note with participants for review and feedback. The note provided overviews of the history of definitions of treatment outcomes and of recent developments in TB treatment and diagnostics for treatment monitoring. It also provided a rationale for potential changes in the definitions of treatment outcomes, with the main reasons for changes being that:

- recent DR-TB treatment regimens are shorter, whereas the current definitions are mainly applicable to longer regimens;
- the all-oral nature of recommended regimens departs from the traditional intensive and continuation phases, whereas the current definitions include timing of culture conversion;
- expected treatment response thresholds occur earlier with new combinations of medicines, whereas the current definitions link assessment to bacteriological conversion; and
- there is still no reliable, suitable and universally applicable biomarker for treatment follow-up and monitoring; thus, a clear definition of bacteriological conversion and reversion is needed to inform the treatment regimen (i.e. whether to continue, halt or modify it).

The difference in treatment outcome definitions for DR-TB and DS-TB is also considered a challenge for implementation. Hence, it would be ideal to have a simplified set of treatment outcome definitions, applicable to both DR-TB and DS-TB.

The concept note proposed three options for outcome definitions to be discussed at the consultation. Options 1 and 2 related to DR-TB treatment outcomes only, whereas option 3 was applicable to both DR-TB and DS-TB.

During the consultation, participants identified general principles that are important and relevant to the revision of treatment outcome definitions, and suggested that the revised definitions will need to:

- be simple and, if possible, applicable to treatment of both DS-TB and DR-TB;
- be applicable to treatment regimens of different lengths;
- de-emphasize the traditional division between intensive and continuation phases;
- identify the appropriate threshold for bacteriological conversion (or reversion) in relation to the definitions of “treatment failed”, “cured” and “treatment completed”;
- consider the use of appropriate diagnostics for treatment monitoring;
- have clear parameters for defining treatment failure, based on a decision to change or stop treatment, or reliable evidence for non-response; and
- be practical for clinical and programmatic monitoring, and feasible for national TB programmes (NTPs) to implement.

The consultation highlighted the following strategic issues, which should guide the development of new treatment outcome definitions:

- Harmonization of treatment outcomes for DS-TB and DR-TB is needed, although some peculiarities and specifics should remain (e.g. treatment monitoring by sputum culture for DR-TB and by sputum microscopy for DS-TB).
- Despite some distinct phases remaining in current regimens, the overall trend is towards monotonous regimens. Thus, linking definitions to treatment phases should be avoided, which means that the time threshold to declare cure or treatment failure should be revised.
- While considering new treatment monitoring tools, we will continue to rely on the available tools (i.e. sputum culture for DR-TB and sputum microscopy for DS-TB), despite their drawbacks.
- At the end of treatment, it is important and feasible for programmes to ascertain cure. The idea of sustained cure may have value, but perhaps only in operational research, depending on needs and the resources available.

Participants spent some time discussing proposed definitions of the treatment outcome categories: “treatment failed”, “cured”, “treatment completed”, “died”, “lost to follow-up” and “not evaluated”.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23985

